Sandoz pulls injectable methotrexate due to particulate matter

05/22/2013 | MedPage Today (free registration)

Sandoz recalled two lots of its methotrexate sodium USP, 25 mg/mL, 40 mL vial injectable drug, which is indicated for rheumatoid arthritis, severe psoriasis and neoplastic diseases. The drugmaker found particulate matter in vials of lots CL0996 and CJ4948 while performing a routine quality inspection. Parenteral injection of the recalled products "can lead to microembolisation in areas where the particles lodge," the FDA warned in its recall notice.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX